Choline pivaloyl ester enhances brain expression of both nerve growth factor and high-affinity receptor TrkA, and reverses memory and cognitive deficits, in rats with excitotoxic lesion of nucleus basalis magnocellularis

Behavioural Brain Research

Volumn 190, Issue 1, 2008, Pages 22-32

  Rispoli, Vincenzo ^a   Marra, Rosario ^b   Costa, Nicola ^a   Rotiroti, Domenicantonio ^a   Tirassa, Paola ^c   Scipione, Luigi ^d   De Vita, Daniela ^d   Liberatore, Felice ^d   Carelli, Vincenzo ^d  

^a Department of Pharmacobiological Sciences   (Italy)

^b INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^c CNR   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer's disease; AMPA lesioned rat NBM; Choline pivaloyl ester; Electroencephalography; Memory and learning performances; Nerve growth factor; Tyrosine kinase A receptor

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; CHOLINE DERIVATIVE; CHOLINE PIVALOYL ESTER; NERVE GROWTH FACTOR; PROTEIN TYROSINE KINASE A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXCITOTOXICITY; HIPPOCAMPUS; MAGNOCELLULAR NUCLEUS; MALE; MEMORY DISORDER; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

ANIMALS; BASAL NUCLEUS OF MEYNERT; BEHAVIOR, ANIMAL; BRAIN; CHOLINE O-ACETYLTRANSFERASE; COGNITION DISORDERS; CYCLOPENTANES; ELECTROENCEPHALOGRAPHY; FUNCTIONAL LATERALITY; GENE EXPRESSION REGULATION; MALE; MAZE LEARNING; MEMORY DISORDERS; NERVE GROWTH FACTOR; NEUROPSYCHOLOGICAL TESTS; NEUROTOXICITY SYNDROMES; RATS; RATS, WISTAR; REACTION TIME; RECEPTOR, TRKA; TIME FACTORS;

EID: 41949132598     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2008.02.002     Document Type: Article

References (66)

1. Alkondon M., Pereira E.F.R., Cortes W.S., Maelicke A., and Albuquerque E.X. Choline is a selective agonist of α7 nicotinic acetylcholine receptors in rat brain neurons. Eur J Neurosci 9 (1997) 2734-2742
2. Allen S.J., and Dawbarn D. Clinical relevance of the neurotrophins and their receptors. Clin Sci 110 (2006) 175-191
3. Allen N.H.P., and Burns A. The treatment of Alzheimer's disease. J Psychopharmacol 9 (1995) 43-56
4. Bartolini L., Casamenti F., and Pepeu G. Aniracetam restores object recognition impaired by age, scopolamine, and nucleus basalis lesions. Pharmacol Biochem Behav 53 (1996) 277-283
5. Bartus R.T., Dean III R.L., Beer B., and Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982) 408-417
6. Belluardo N., Mudo' G., Blum M., and Fuxe K. Central nicotinic receptors, neurotrophic factors and neuroprotection. Behav Brain Res 113 (2000) 21-34
7. Boissiere F., Faucheux B., Ruberg M., Agid Y., and Hirsch E.C. Decreased TrkA gene expression in cholinergic neurons in the Striatum and basal forebrain of patient with Alzheimer's disease. Expt Neurol 145 (1997) 245-252
8. Carelli V, Liberatore F, Scipione L, Rotiroti D, Rispoli V, Cardellini M. Choline derivatives for the treatment of Alzheimer's disease. Patent IT MI 2000 A000898-21-4-2000, EP 1925883.9-10-4-2001; C.A. 2001; 135(24): 344212m.
9. Chao M.V., Rajagopal R., and Lee F.S. Neurotrophin signalling in health and disease. Clin Sci 110 (2006) 167-173
10. Collerton D. Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience 19 (1986) 1-28
11. Cossette P., Umbriaco D., Zamar N., Hamel E., and Descarries L. Recovery of choline acetyltransferase activity without sprouting of the residual acetylcholine innervation in adult rat cerebral cortex after lesion of the nucleus basalis. Brain Res 630 (1993) 195-206
12. Coyle J.T., Price D.L., and DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219 (1983) 1184-1190
13. Crutcher K.A., Scott S.A., Liang S., Everson W.V., and Weingartner J. Detection of NGF-like activity in human brain tissue: increased level in Alzheimer's disease. J Neurosci 13 (1993) 2540-2450
14. Dawbarn D., and Allen S.J. Neurotrophins and neurodegeneration. Neuropath Appl Neuro 29 (2003) 211-230
15. Decker M.W., Majchrzak M.J., and Anderson D.J. Effect of nicotine on spatial memory deficits in rats with septal lesions. Brain Res 572 (1992) 281-285
16. Ennaceur A., and Delacour J. A new one-trial test for neurobiological studies of memory in rats: behavioural data. Behav Brain Res 31 (1988) 47-59
17. Everitt B.J., and Robbins T.W. Central cholinergic system and cognition. Ann Rev Psychol 48 (1997) 649-684
18. Fischer W., Bjorklund A., Chen K., and Gage N.H. NGF improves spatial memory in aged rodents as a function of age. J Neurosci 11 (1991) 1889-1906
19. Fischer W., Wictorin K., Bjorklund A., Williams L.R., Varon S., and Gage F.H. Amelioration of cholinergic neuron atrophy and spatial memory impairments in aged rats by nerve growth factor. Nature 329 (1987) 65-68
20. Francis P.T., Palmer A.M., Snape M., and Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease, a review of progress. J Neurol Neurosurg PS 66 (1999) 137-147
21. French S.J., Humby T., Horner C.H., Sofroniew M.V., and Rattray M. Hyppocampal neurotrophin and Trk receptors mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine. Mol Brain Res 67 (1999) 124-136
22. Goedert M., Fine A., Hunt S.P., and Ulrich A. Nerve growth factor in peripheral and central rat tissue and in human central nervous system: lesion effects in the rat brain and levels in Alzheimer's disease. Mol Brain Res 1 (1986) 85-92
23. Haroutunian V., Kanof P.D., and Davis K.L. Partial reverse of lesion induced deficits in cortical cholinergic markers by nerve growth factor. Brain Res 386 (1986) 397-399
24. Hefti F., Hartikka J., Knusel B., La Plume M.O., and Mash D.C. Nerve growth factor and cholinergic neurons of the mammalian brain. In: Steriade M., and Biesold D. (Eds). Brain Cholinegic System (1990), Oxford University Press, New York 173-201
25. Hefty F., and Mash D.F. Localization of NGF receptors in normal brain and in Alzheimer's disease. Neurobiol Aging 10 (1989) 75-87
26. Katzman R. Medicinal progress in Alzheimer's disease. N Engl J Med 314 (1986) 964-973
27. Korsching S. The role of nerve growth factor in the CNS. Trends Neurosci. 9 (1986) 570-573
28. Jones G.M.M., Sahakian B.J., Levy R., Warburton D.M., and Gray J.A. Effects of acute subcutaneous nicotine on attention, information, processing and short term memory in Alzheimer's disease. Psycopharmacology 108 (1992) 485-494
29. Jonnala R.R., and Buccafusco J.J. Relationship between the increased cell surface α7 nicotinic receptors expression and neuroprotection induced by several nicotinic receptor agonists. J Neurosci Res 66 (2001) 565-572
30. Jonnala R.R., Graham III J.H., Terry Jr. A.V., Beach J.W., Young J.A., and Buccafusco J.J. Relative levels of cytoprotection produced by analogs of choline and the role of α7 nicotinic acetylcholine receptors. Synapse 47 (2003) 262-269
31. Lad S.P., Need K.E., and Mufson E.J. Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr. Drug Targets Neurol Disord 2 (2003) 315-334
32. Ladner C.J., and Lee J.M. Pharmacological treatment of Alzheimer's disease: the cholinergic hypothesis revisited. J Neuropathol Exp Neurol 57 (1998) 719-731
33. Levi-Montalcini R. The nerve growth factor 35 years later. Science 237 (1987) 1154-1162
34. Levin E.D. Nicotinic system and cognitive function. Psycopharmacology (Berl) 108 (1992) 417-431
35. Levin E.D., Christopher N.G., Briggs S.J., and Rose J.E. Chronic nicotine reverses working memory deficits caused by lesions of the fimbria or medial basalocortical projection. Cogn Brain Res 1 (1993) 137-143
36. Levin E.D., and Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psycopharmacology 138 (1998) 217-230
37. Mandel R.J., Gage F.H., and Thal L.J. Spatial learning in rats: correlation with cortical cholinergic acetyltransferase and improvement with NGF following NBM damage. Expt Neurol 104 (1989) 208-217
38. Mesulam M.M., and Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observation based on the distribution of acetylcholinesterase and choline acetyltransferase. J Com Neurol 275 (1988) 216-240
39. Mesulam M.M., Mufson E.J., Levey Q.I., and Wainer B.H. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area diagonal band nuclei; nucleus basalis, substantia innominata, and hypotalamus in the rhesus monkey. J Com Neurol 214 (1983) 170-197
40. Meyer E.M., Barrnett R.J., and Cooper J.R. Neurochemical characterization of an antimonycholine analog in rat cortical synaptosomes. J Neurochem 39 (1998) 321-326
41. Mike A., Castro N.G., and Albuquerque E.X. Choline and acetylcholine have similar kinetic properties of activation and desensitization of the α7 nicotinic receptors in rat hippocampal neurons. Brain Res 882 (2000) 155-168
42. Morris R.G.M. Development of water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11 (1984) 47-60
43. Mufson E.J., Lavine N., Jaffar S., Kordover J.H., Quirion R., and Sargovi H.U. Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Expt Neurol 146 (1997) 91-103
44. Mufson E.J., Ginsberg S.D., Ikonomovic M.D., and DeKosky S.T. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat 26 (2003) 233-242
45. Nonomura T., and Hatanaka H. Neurotrophic effects of brain-derived neurotrophic factor on basal forebrain cholinergic neurons in culture from postnatal rats. Neurosci Res 14 (1992) 226-233
46. Nordberg A. Biological markers and the cholinergic hypothesis in Alzheimer's disease. Acta Neurol Scand Suppl 85 (1992) 54-58
47. O'Neill M.J., Murray T.K., Lakics V., Visanji N.P., and Duty S. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr Drug Target CNS Neurol Disord 1 4 (2002) 399-411
48. Papke R.L., Bencherif M., and Lippiello P. An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the alpha 7 subtype. Neurosci Lett 213 (1996) 201-204
49. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1980), Academic Press, New York
50. Perry E.K., Perry R.H., Blessed G., and Tomlison B.E. Changes in brain cholinesterases in senile dementia of the Alzheimer type. Neuropathol Appl Neurobiol 4 (1978) 273-277
51. Rispoli V., Rotiroti D., Carelli V., Liberatore F., Scipione L., Marra R., et al. Choline pivaloyl esters improve in rats cognitive and memory performances impaired by scopolamine treatment or lesions of the nucleus basalis of Meynert. Neurosci Lett 356 (2004) 199-202
52. Rispoli V., Rotiroti D., Carelli V., Liberatore F., Scipione L., Marra R., et al. Electroencephalographic effects induced by choline pivaloyl esters in scopolamine treated or nucleus basalis magnocellularis lesioned rats. Pharmacol Biochem Behav 78 (2004) 667-673
53. Rispoli V., Marra R., Costa N., Scipione L., Rotiroti D., De Vita D., et al. Choline pivaloyl ester strengthened the benefit effects of Tacrine and Galantamine on electroencephalographic and cognitive performances in nucleus basalis magnocellularis lesioned and aged rats. Pharmacol Biochem Behav 84 (2006) 453-467
54. Salehi A., Verhaagen J., Dijkhuizen P.A., and Swaab D.F. Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease. Neuroscience 75 (1996) 373-387
55. Sculte-Herbrüggen O., Braun A., Rochlitzer S., Jockers-Scherubl M.C., and Hellweg R. Neurotrophic factors-a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases?. Curr Med Chem 14 22 (2007) 2318-2329
56. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 6 (1991) 487-498
57. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81 (2001) 741-766
58. Shimohama S., and Kihara T. Nicotinic receptor-mediated protection against beta-amyloid neurotoxicity. Biol Psychiatry 49 (2001) 233-239
59. Shaughnessy L.W., Mundy W.R., Tilson H.A., and Barone Jr. S. Time course of changes in cholinergic and neurotrophin-related markers after infusion of colchicines into the basal forebrain. Brain Res 781 (1998) 62-77
60. Strahlendorf J.C., Acosta S., Miles R., and Strahlendorf H.K. Choline blocks AMPA-induced dark cell degeneration of purkinje neurons: potential role of the α7 nicotinic receptor. Brain Res 901 (2001) 71-78
61. Tuszynski M.H., Thal L., Pay M., Salmon D.P., Sang U.H., Bakay R., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11 5 (2005) 551-555
62. Uteshev V.V., Meyer E.M., and Papke R.L. Regulation of neuronal function by choline and 4OHGTS - 21 through α7-nicotinic receptors. J Neurophisiol 89 (2003) 1797-1806
63. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., and DeLong M.R. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10 (1981) 122-126
64. Will B., and Hefti F. Behavioural and neurochemical effects of chronic intraventricular injection of nerve growth factor in adult rats with fimbria lesions. Behav Brain Res 17 (1985) 17-24
65. Yamada K., Nitta A., Hasegawa T., Fuji K., Hiramatsu M., Kameyama T., et al. Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. Behav Brain Res 83 1-2 (1997) 117-122
66. Yamashita H., and Nakamura S. Nicotine rescue PC12 cells from death induced by nerve growth factor deprivation. Neurosci Lett 213 (1996) 145-147